West Pharmaceutical Services, Inc. - 10-Q Summary
Business Context and Reporting Period
Company: West Pharmaceutical Services, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: West is a global manufacturer of components and systems for injectable drug delivery and plastic packaging for healthcare and consumer products. Operations are divided into two segments: Pharmaceutical Systems (primary packaging) and Tech Group (custom contract manufacturing). The company is a large accelerated filer with significant international exposure, particularly to the Euro and British Pound.
Key Financial Metrics
| Metric ($ millions) | Q2 2009 | Q2 2008 | YTD 2009 | YTD 2008 |
|---|---|---|---|---|
| Net Sales | $261.0 | $279.3 | $503.4 | $550.0 |
| Gross Profit | $78.7 | $83.6 | $148.0 | $167.1 |
| Gross Margin | 30.2% | 29.9% | 29.4% | 30.4% |
| Operating Profit | $28.6 | $42.6 | $49.9 | $80.7 |
| Net Income (Common Shareholders) | $19.7 | $28.7 | $35.1 | $55.0 |
| Diluted EPS | $0.57 | $0.82 | $1.03 | $1.58 |
| Cash from Operations (YTD) | $46.1 | $48.9 | ||
| Cash & Equivalents (End of Period) | ||||
| Total Debt | $390.2 | $398.2 | ||
| Working Capital | $234.7 | $264.9 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 6.6% in Q2 and 8.5% YTD compared to 2008. Excluding unfavorable foreign currency impacts ($20.2M in Q2, $40.5M YTD), sales were relatively flat (up 0.7% in Q2, down 1.1% YTD). The decline was driven by customer inventory reductions, economic uncertainty, and lower consumer product spending.
- Profitability Compression: Operating profit fell significantly (33% in Q2, 38% YTD) due to lower sales volumes, unfavorable product mix, and higher SG&A costs. Pharmaceutical Systems margins declined due to higher production costs and lower capacity utilization. Conversely, Tech Group margins improved due to better European sales mix and efficiency.
- SG&A Increases: Selling, General, and Administrative expenses rose $4.2M in Q2 and $7.0M YTD. Key drivers included a $2.6M increase in U.S. pension costs (due to lower plan asset values) and higher compensation/depreciation costs.
- One-Time Items: The 2008 periods included a $6.6M gain on a contract settlement with Nektar Therapeutics (Exubera device), which is absent in 2009. 2009 included minor restructuring charges ($0.4M in Q2, $1.1M YTD) related to the Tech Group.
- Tax Rate: The effective tax rate decreased to 23.8% in Q2 2009 (from 27.6% in 2008) and 20.0% YTD (from 26.0% in 2008), aided by a $1.7M discrete tax benefit from audit completions and expiring tax years.
Guidance, Outlook, and Risks
- Outlook: Management expects the U.S. dollar to remain relatively strong in 2009, negatively impacting financial results. Orders on-hand as of June 30, 2009, are stronger on a constant-currency basis than the prior year, partly due to H1N1 influenza preparedness orders. Management cautiously expects full-year 2009 sales (excluding FX) to exceed 2008 levels if current trends continue.
- Capital Spending: Full-year 2009 capital spending is forecast between $110.0M and $120.0M (down from $138.6M in 2008) due to discretionary reductions and project delays pending market assessment.
- Recent Acquisition: On July 6, 2009, the company acquired the drug delivery business assets of Plastef Investissements SA for approximately $17.0M cash plus contingent consideration.
- Risks:
- Foreign Exchange: Significant exposure to Euro, British Pound, and Yen fluctuations.
- Economic Downturn: Continued weakness in consumer products and healthcare spending; customer inventory reduction programs.
- Supply Chain: Dependence on single-source suppliers and potential raw material price escalation (petroleum-based).
- Pension Funding: Significant pension expense increases due to lower asset returns and funding obligations.
Investor Verification Checklist
- Constant Currency Performance: Verify the organic growth rate by excluding the significant negative impact of foreign currency translation on sales and operating profit.
- Pension Cost Trajectory: Confirm the full-year impact of the increased U.S. pension expense ($10.4M higher than 2008) and its effect on future cash flows.
- H1N1 Order Conversion: Assess the extent to which H1N1-related backlog orders will convert to actual revenue in the second half of 2009.
- Tech Group Restructuring: Monitor the completion of the Tech Group restructuring plan and its impact on future operating leverage.
- Capital Allocation: Review the revised capital expenditure guidance ($110M-$120M) and the status of the China plastics plant and European expansions.